IDEXX Laboratories, Inc. (IDXX)
Healthcare • Diagnostics & Research
StockNasdaqGSUnited StatesUS45168D1046
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by IDEXX Laboratories, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:26. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 01 Feb 2027 08:00 | 3.32 | — | — | Upcoming |
| 02 Nov 2026 06:00 | 3.71 | 4.01 | +8.0% | Beat |
| 04 Aug 2026 06:00 | 3.93 | 4.27 | +8.5% | Beat |
| 05 May 2026 06:00 | 3.41 | 3.47 | +1.7% | Beat |
| 02 Feb 2026 06:00 | 2.94 | 3.08 | +4.8% | Beat |
| 03 Nov 2025 06:00 | 3.15 | 3.40 | +8.1% | Beat |
| 04 Aug 2025 06:00 | 3.30 | 3.63 | +10.0% | Beat |
| 01 May 2025 06:00 | 2.84 | 2.96 | +4.1% | Beat |
| 03 Feb 2025 06:00 | 2.40 | 2.62 | +9.2% | Beat |
| 31 Oct 2024 06:00 | 2.69 | 2.80 | +4.3% | Beat |
| 06 Aug 2024 06:00 | 2.87 | 3.02 | +5.2% | Beat |
| 01 May 2024 06:00 | 2.68 | 2.81 | +4.8% | Beat |
| 05 Feb 2024 06:00 | 2.12 | 2.32 | +9.4% | Beat |
| 01 Nov 2023 06:00 | 2.37 | 2.53 | +6.7% | Beat |
| 01 Aug 2023 06:00 | 2.47 | 2.67 | +8.2% | Beat |
| 02 May 2023 06:00 | 2.43 | 2.55 | +4.9% | Beat |
| 06 Feb 2023 06:00 | 1.92 | 2.05 | +6.5% | Beat |
| 01 Nov 2022 06:00 | 2.04 | 2.15 | +5.5% | Beat |
| 02 Aug 2022 06:00 | 1.63 | 1.56 | -4.1% | Miss |
| 04 May 2022 06:00 | 2.25 | 2.27 | +1.0% | In line |
| 02 Feb 2022 06:00 | 1.72 | 1.89 | +9.9% | Beat |
| 02 Nov 2021 06:00 | 1.91 | 2.03 | +6.1% | Beat |
| 30 Jul 2021 06:00 | 2.04 | 2.34 | +14.6% | Beat |
| 04 May 2021 06:00 | 1.72 | 2.35 | +36.4% | Beat |
| 02 Feb 2021 06:00 | 1.39 | 1.76 | +26.5% | Beat |
| 29 Oct 2020 06:00 | 1.44 | 1.69 | +17.4% | Beat |
| 31 Jul 2020 06:00 | 1.17 | 1.72 | +46.7% | Beat |
| 30 Apr 2020 07:00 | 1.20 | 1.29 | +7.7% | Beat |
| 31 Jan 2020 06:00 | 0.90 | 1.04 | +15.1% | Beat |
| 31 Oct 2019 06:00 | 1.14 | 1.24 | +8.9% | Beat |
| 01 Aug 2019 06:00 | 1.37 | 1.43 | +4.3% | Beat |
| 01 May 2019 06:00 | 1.06 | 1.17 | +10.8% | Beat |
| 01 Feb 2019 06:00 | 0.91 | 0.98 | +8.0% | Beat |
| 01 Nov 2018 06:00 | 0.97 | 1.05 | +8.1% | Beat |
| 01 Aug 2018 06:00 | 1.17 | 1.23 | +5.2% | Beat |
| 04 May 2018 06:00 | 0.92 | 1.01 | +9.9% | Beat |
| 01 Feb 2018 06:00 | 0.73 | 0.77 | +5.8% | Beat |
| 31 Oct 2017 07:00 | 0.74 | 0.79 | +6.3% | Beat |
| 01 Aug 2017 07:00 | 0.85 | 0.95 | +11.8% | Beat |
| 28 Apr 2017 07:00 | 0.60 | 0.77 | +27.3% | Beat |
| 02 Feb 2017 07:00 | 0.51 | 0.58 | +14.1% | Beat |
| 01 Nov 2016 07:00 | 0.60 | 0.62 | +3.6% | Beat |
| 02 Aug 2016 07:00 | 0.62 | 0.74 | +19.4% | Beat |
| 29 Apr 2016 07:00 | 0.47 | 0.51 | +9.4% | Beat |
| 29 Jan 2016 07:00 | 0.44 | 0.48 | +10.3% | Beat |
| 28 Oct 2015 06:00 | 0.53 | 0.54 | +2.9% | Beat |
| 30 Jul 2015 07:00 | 0.57 | 0.60 | +4.7% | Beat |
| 28 Apr 2015 07:00 | 0.49 | 0.49 | +0.4% | In line |
| 30 Jan 2015 07:00 | 0.38 | 0.48 | +24.7% | Beat |
| 24 Oct 2014 07:00 | 0.43 | 0.53 | +21.3% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 4.3B | +10.4% | 1.1B | 24.6% | 13.08 | +22.6% | 1B |
| 2024 | 3.9B | +6.5% | 887.9M | 22.8% | 10.67 | +6.1% | 798.1M |
| 2023 | 3.7B | +8.7% | 845M | 23.1% | 10.06 | +25.3% | 772.9M |
| 2022 | 3.4B | — | 679.1M | 20.2% | 8.03 | — | 384.1M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 13 Nov 2026 | 706.40 | 711.23 | 702.53 | 705.48 | +1.07% | 86,068 | |
| 12 Nov 2026 | 711.68 | 712.88 | 696.72 | 698.02 | -0.65% | 487,600 | |
| 11 Nov 2026 | 688.04 | 703.84 | 680.00 | 702.59 | +0.85% | 423,300 | |
| 10 Nov 2026 | 700.00 | 700.00 | 682.58 | 696.64 | -1.42% | 463,900 | |
| 09 Nov 2026 | 682.35 | 709.26 | 680.89 | 706.65 | +4.53% | 703,700 | |
| 06 Nov 2026 | 652.12 | 680.57 | 650.00 | 676.04 | +0.79% | 589,000 | |
| 05 Nov 2026 | 702.00 | 704.03 | 664.81 | 670.71 | -3.99% | 873,000 | |
| 04 Nov 2026 | 686.23 | 713.74 | 681.70 | 698.55 | +3.94% | 1,398,900 | |
| 03 Nov 2026 | 662.26 | 681.50 | 655.52 | 672.04 | +0.06% | 1,188,100 | |
| 02 Nov 2026 | 625.00 | 673.19 | 620.20 | 671.64 | +21.85% | 1,976,100 | |
| 1,250 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- How IDEXX Stock Is Engineered To Make Money For You (opens in a new tab) Trefis · 07 Nov 2026 01:10
- 3 Reasons Growth Investors Will Love Idexx (IDXX) (opens in a new tab) Zacks · 06 Nov 2026 16:45
- Board Member At IDEXX Laboratories Sells $844K Of Stock (opens in a new tab) Benzinga · 06 Nov 2026 11:01
- Executive Vice President At IDEXX Laboratories Sells $2.74M Of Stock (opens in a new tab) Benzinga · 06 Nov 2026 11:01
- Major Decision: Sharon E Underberg Exercises Options, Realizing $3.35M At IDEXX Laboratories (opens in a new tab) Benzinga · 06 Nov 2026 11:01
- IDEXX Laboratories: Great Company, But Too Expensive (Rating Downgrade) (opens in a new tab) SeekingAlpha · 04 Nov 2026 08:35
- IDEXX Laboratories: Q3 Results Confirm They Are Best-In-Class (opens in a new tab) SeekingAlpha · 04 Nov 2026 06:07
- IDEXX Laboratories (IDXX) Q3 Earnings Leave Its Premium Valuation In Focus (opens in a new tab) Simply Wall St. · 03 Nov 2026 23:22
- IDEXX Laboratories Delivered Strong Results Despite Lackluster Vet Visit Backdrop, UBS Says (opens in a new tab) MT Newswires · 03 Nov 2026 18:04
- Morgan Stanley Maintains Overweight on IDEXX Laboratories, Raises Price Target to $810 (opens in a new tab) Benzinga · 03 Nov 2026 13:35
- Idexx Laboratories (IDXX) Crossed Above the 200-Day Moving Average: What That Means for Investors (opens in a new tab) Zacks · 03 Nov 2026 13:30
- Company News for Nov 3, 2026 (opens in a new tab) Zacks · 03 Nov 2026 13:22
- UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $700 (opens in a new tab) Benzinga · 03 Nov 2026 12:00
- IDEXX stock soars 21.9% after earnings beat and higher outlook (opens in a new tab) TheStreet · 03 Nov 2026 00:00
- Non-AI stock surges 20% after earnings beat and raised outlook (opens in a new tab) TheStreet · 02 Nov 2026 23:14
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 698.02 USD
- Market cap
- 55.0B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 19.6 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 24.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 18.8 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 2.9 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 3.9 / 10 |
|
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 47.04× | Weak | 30.56× |
| P/E (forward) | 41.32× | Weak | 14.16× |
| Price / book | 29.42× | Weak | 3.5× |
| Price / sales | 11.8× | Weak | 3.33× |
| EV / EBITDA | 33.33× | Weak | 11.19× |
| Free cash flow yield | 1.9% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 62.7% | Good | 54.9% |
| Operating margin | 32.5% | Good | 5.8% |
| Net margin | 25.4% | Good | 1.2% |
| Return on equity | 68.9% | Good | 4.4% |
| Return on assets | 26.7% | Good | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 8.5% | Good | 10.1% |
| EPS growth / year | 17.7% | Good | 10.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.52× | Good | 0.4× |
| Net debt / EBITDA | 0.46× | Good | 1.46× |
| Interest cover | 35.01× | Good | 2.17× |
| Current ratio | 1.19× | Fair | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow IDXX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.